Zytostatische Adjuvanstherapie beim Bronchuskarzinom

  • K Karrer
Conference paper
Part of the Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 22)

Zusammenfassung

Schon seit längerer Zeit sind erfahrene Chirurgen übereinstimmend davon überzeugt, daß sich die Ergebnisse der chirurgischen Behandlung des Bronchuskarzinoms kaum mehr wesentlich steigern lassen werden [78, 99].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Addis G. J.: Treatment of bronchial carcinoma. Lancet 7970, 1184 (1976)Google Scholar
  2. 2.
    Adelberger L., Wörn H.: Erfahrungen und Aussichten der kombinierten chirurgisch-zytostatischen Behandlung des Bronchialkarzinomes. Mitteilungsdienst d. Ges. z. Bek. d. Krebskrankh. 8, 521 (1962)Google Scholar
  3. 3.
    Adelberger L.: Die Chemotherapie bei malignen Tumoren des Brustraumes. Med. Welt 18/39, 2296 (1967)Google Scholar
  4. 4.
    Amery W. K.: Overview of other controlled clinical data: an attempt at defining the future position of levamisole in cancer therapy. Symposium on Immunotherapy of Malignant Diseases, Nov. 9–10, 1977, ViennaGoogle Scholar
  5. 5.
    Amery W. K.: Adjuvant therapy of lung cancer. Brit. Med. J. 1, 573 (1977)CrossRefGoogle Scholar
  6. 6.
    Arnal M. L., Dold U., Ehlers C. Th., Gögler E., Hamperl H., Karrer K., Oberhoffer G., Ott G., Pascher W., Proppe A., Scheibe 0., Schmolling E., Spiessl B., Thurmayer R., Wildner E. P.: Zur KIassifizierung der Geschwulstkrankheiten. Der „gesicherte” TNM-Schlüssel (Erweiterungsvorschlag zu den „General Rules” der UICC). Meth. Inf. Med. 6, 70 (1967)Google Scholar
  7. 7.
    Berndt H., Krüger C. W.: Die klinische Klassifikation des Lungenkrebses nach Feinstein. Arch. Geschwulstforsch. 34, 211 (1969)PubMedGoogle Scholar
  8. 8.
    Block J. B., Isacoff W. H.: Adjuvant chemotherapy in cancer. Seminars in Oncol. 4, 109 (1977)Google Scholar
  9. 9.
    Bomford R., Olivetto M.: Inhibition by corynebacterium parvum of lung nodule formation by Lv. injected fibrosarcoma cells. In „Corynebacterium parvum — Application in experimental and clinical oncology”. p. 268 (B. Halpern Ed.) New York: Plenum Press 1974Google Scholar
  10. 10.
    Brunner K. W., Marthaler Th., Müller W.: Unfavourable effects of long-term adjuvant chemotherapy with endoxan in radically operated bronchogenic carcinoma. Europ. J. Cancer 7, 285 (1971)CrossRefGoogle Scholar
  11. 11.
    Buyze E. A. C., Nelemans F. A.: A study of postoperative cytostatic medication in patients with operable carcinoma of the lung. Arzneimittel-Forsch. 23, 860 (1973)Google Scholar
  12. 12.
    Campobasso 0., Invernizzi B., Musso M., Berrino F.: Survival rates of lung cancer according to histological type. Brit. J. Cancer 29, 240 (1974)PubMedCrossRefGoogle Scholar
  13. 13.
    Carter S. K.: Immunotherapy in the strategy of cancer treatment. Cancer Immunol. Immunother. 1, 115 (1976)CrossRefGoogle Scholar
  14. 14.
    Castro J. E., Sadler T. E., Jones P.: The effects and mode of action of corynebacterium parvum on a metastasising tumour. Bull. Soc. Int. Chir. 34, 461 (1975)Google Scholar
  15. 15.
    Castro J. E., Sadler T. E.: Combined surgery and corynebacterium parvum for treatment of a metastasising tumor in mice. Brit. J. Surg. 62, 22 (1975)Google Scholar
  16. 16.
    Cheng V. S. T., Suit H. D., Wang C. C., Cummings C.: Non-specific immunotherapy by corynebacterium parvum. Cancer 37, 1687 (1976)PubMedCrossRefGoogle Scholar
  17. 17.
    Crosbie W. A., Kamdar H. H., Belcher J. R.: A controlled trial of vinblastine sulphate in the treatment of cancer of the lung. Brit. J. Dis. Chest 60, 28 (1966)PubMedCrossRefGoogle Scholar
  18. 18.
    Cruz E. P., McDonald G. O., Cole W. H.: Prophylactic treatment of cancer. Surgery 40, 291 (1956)PubMedGoogle Scholar
  19. 19.
    Denk W., Karrer K.: Modellversuch einer Rezidivprophylaxe des Karzinoms. Wr. Klin. Wschr. 67, 986 (1955)Google Scholar
  20. 20.
    Denk W., Karrer K.: Untersuchungen über die Möglichkeit einer Immunoprophylaxe des Karzinomes. Österr. Zschr. f. Erforschung und Bekämpfung der Krebskrankheit 25, 30 (1970)Google Scholar
  21. 21.
    Dimitrov N. V., Singh T., Conroy J., Suhrland G. L.: Combination therapy with corynebacterium parvum and adriamycin in patients with lung carcinomas. Proc. 12th ann. meeting of the Amer. Soc. Clin. Oncol., Toronto, May 4–8, 1976, Abstr. C–222Google Scholar
  22. 22.
    Dolton E. G.: Combined surgery and chemotherapy for carcinoma of bronchus. Lancet 1, 40 (1970)PubMedCrossRefGoogle Scholar
  23. 23.
    Feinstein A. R.: Symptomatic patterns, biologic behavior and prognosis in cancer of the lung. Ann. of Internal Med. 61, 27 (1964)Google Scholar
  24. 24.
    Fisher B., Rabin H., Sartrano G., Ennis L., Wolmark N.: Observation following corynebacterium parvum administration in patients with advanced malignancy. — A phase I study. Cancer 38, 119 (1976)Google Scholar
  25. 25.
    Galle P.: Ergebnisse der mehrjährigen postoperativen Rezidivprophylaxe mit Endoxan nach Radikaloperation maligner Tumoren. Krebsarzt 22/2, 91 (1967)Google Scholar
  26. 26.
    Garin A. M., Lichinicer M. R.: Methodical aspects of cancer chemotherapy after radical surgery. Cancer Chemother. Rep. 58, 129 (1974)Google Scholar
  27. 27.
    Gütgemann A., Kreutzberg B., Lichtenthäler J., Savić B.: Ergebnisse und Erfahrungen zum Bronchialkarzinom. Die Med. Welt 27, 835 (1976)Google Scholar
  28. 28.
    Halpern B. N.: Stimulation de l’activite phagocytairé phagocytaire du systeme reticuloendothelial provoquée par Corynebacterium parvum. J. Retic. Soc. 1, 77 (1964)Google Scholar
  29. 29.
    Halpern B. N., Biozzi G., Stiffel C., Mouton D.: Inhibition of tumor growth by administration of killed corynebacterium parvum. Nature 212, 853 (1966)PubMedCrossRefGoogle Scholar
  30. 30.
    Halpern B.: Corynebacterium parvum-Applications in experimental and clinical Oncology. Plenum Press — New York—London 1975Google Scholar
  31. 31.
    Han T., Takita H.: Inhibition of mixed lymphocyte reaction by thoracic duct lymph: Removal of inhibitory effect by thoracic duct drainage in lung cancer. J. of Surg. Oncol. 8, 237 (1976)CrossRefGoogle Scholar
  32. 32.
    Hersh E. M., Mavligit G. M., Gutterman J. U.: Immunotherapy as related to lung cancer: A review. Sem. in Oncol. 1, 273 (1974)Google Scholar
  33. 33.
    Higgins G. A., Humphrey E. W.: Cytoxan as an adjuvant to surgery for lung cancer. J. Surg. Oncol.1, 221 (1969)PubMedCrossRefGoogle Scholar
  34. 34.
    Higgins G. A.: Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma. Cancer 30, 1383 (1972)PubMedCrossRefGoogle Scholar
  35. 35.
    Hill L. D., Wright P. W., Hammar S. P., Bernstein I. D., Morgan E. H., Petersen A.: Immunotherapy of resectable, non-oat cell cancer of the lung: a prospective comparison of intrapleural BCG (IP-BCG)+ levamisole versus IP-BCG versus placebo. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr. 24Google Scholar
  36. 36.
    Hinson K. F. W., Miller A. B., Tall R.: An assessment of the World Health Organization classification of the histologic typing of lung tumors applied to biopsy and resected material. Cancer 35, 399 (1975)PubMedCrossRefGoogle Scholar
  37. 37.
    Hirshaut Y., Pinsky C. M., Wanebo H. J., Oettgen H. F.: Design of phase I trials of immunopotentiators for cancer therapy: levamisole and corynebacterium parvum. Ann. New York Akad. Scie. 277, 252 (1976)CrossRefGoogle Scholar
  38. 38.
    Hollinshead A. C.: Immune stimulation with cell fractions and vaccine. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr. 25Google Scholar
  39. 39.
    Holmes C., Golub S. H.: Immunologic defects in lung cancer patients. J. Thorac. Cardiovasc. Surg. 71, 161 (1976)PubMedGoogle Scholar
  40. 40.
    Holmes C., Carmack E., Golub S. H., Sidney H.: Surgical adjuvant immunotherapy studies in patients with lung cancer. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr. 26Google Scholar
  41. 41.
    Humphreys S. R., Karrer K.: Relationship of dose schedules to the effectiveness of adjuvant chemotherapy. Cancer Chemoth. Rep. 54, 379 (1970)Google Scholar
  42. 42.
    Ishikawa S.: Staging system on TNM classification for lung cancer. Jap. J. Clin. Oncol. 6, 19 (1973)Google Scholar
  43. 43.
    Israel L., Galey J.-J.: Expérience préliminaire d’association chirurgie-polychimiothérapie dans les cancers bronchiques. Ann. Chir. Thor. Car. 7, 479 (1968)Google Scholar
  44. 44.
    Israel L., Chahinian P.: Evaluation of the survival gain in 22 measurable lung tumors treated with chemotherapy. Europ. J. Cancer 5, 631 (1969)CrossRefGoogle Scholar
  45. 45.
    Israel L., Mugica J., Chahinian P.: Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test. Biomedicine 19, 68 (1973)PubMedGoogle Scholar
  46. 46.
    Israel L.: Cell-mediated immunity in lung cancer patients: data, problems and propositions. Cancer Chemother. Rep. 4, 279 (1973)Google Scholar
  47. 47.
    Israel, L.: Preliminary results of non specific immunotherapy for lung cancer. Cancer Chemother. Rep. 4, 283 (1973)Google Scholar
  48. 48.
    Israel L.: Immunotherapy with corynebacterium parvum in disseminated cancer. Ann. New York Acad. Scie. 277, 241 (1976)CrossRefGoogle Scholar
  49. 49.
    Israel L., Depierre A.: Long duration complete response to immunotherapy in oat cell carcinomas of the lung. Proc. 12th ann. meeting of the Amer. Soc. Clin. Oncol., Toronto, May 4–8, 1976, Abstr. C–10Google Scholar
  50. 50.
    Israel L., Bonadonna G., Silvester R.: Controlled study with adjuvant radiotherapy, chemotherapy and immunotherapy in operable epidermoid bronchial carcinoma. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr. 28Google Scholar
  51. 51.
    Kanhouwa S. B., Matthews M. J.: Reliability of cytologi~typing of lung cancer. Acta Cytol. 20, 229 (1976)PubMedGoogle Scholar
  52. 52.
    Karrer K.: Zur kombinierten cytostatischen und operativen Behandlung des Carcinoms. Arzneimittel-Forsch. 14, 859 (1964)Google Scholar
  53. 53.
    Karrer K., Humphreys S. R., Goldin A.: Relationship of drug toxicity to chemotherapeutic effectiveness. Antimicrob. Agents and Chernother. 539 (1965)Google Scholar
  54. 54.
    Karrer K., Wurnig P.: Die Verwendbarkeit der histologischen Einteilung des Bronchuskarzinoms für die Klinik. Krebsarzt 21, 325 (1966)Google Scholar
  55. 55.
    Karrer K., Humphreys S. R., Goldin A.: Ein neues experimentelles Modell zum Studium der Beeinfluβbarkeit der Metastasierung maligner Tumoren. Krebsf. u. Krebsbek. 6, 166 (1967)Google Scholar
  56. 56.
    Karrer K.: Ethische und rechtliche Probleme bei der Prüfung und Anwendung von Krebsheilmitteln. Int. Zschr. f. Klin. Pharmakol., Therapie u. Toxikol. 2, 139 (1971)Google Scholar
  57. 57.
    Karrer K., Denck H.: Weitere Vorschläge zur chemotherapeutischen Rezidivprophylaxe des Bronchuskarzinoms. Wr. Med. Wschr. 121, 112 (1971)Google Scholar
  58. 58.
    Karrer K.: Importance of dose schedules in adjuvant chemotherapy. Cancer Chemother. Rep. 56, 35 (1972)Google Scholar
  59. 59.
    Karrer K.: Zur Bedeutung eines Tumormodells für die klinische Chemotherapie maligner Tumoren. Österr. Ärzteztg. 29, 1370 (1974)Google Scholar
  60. 60.
    Karrer K., Pridun N., Denck H., Sighart H.: Polychemotherapie bei Patienten nach radikaler Operation wegen Bronchus-Karzinom. Österr. Zschr. f. Onkol. 3, 127 (1976)Google Scholar
  61. 61.
    Karrer K. : Zur Übertragbarkeit tierexperimenteller Ergebnisse einer zytostatischen Chemotherapie auf den Menschen. Advances in Clin. Pharmacol. 14, 89 (1977)Google Scholar
  62. 62.
    Karrer K., Pridun N., Denck H.: Study of polychemotherapy as surgical adjuvant in lung cancer. Experience of the Viennese Group. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24,1977, Abstr. 31Google Scholar
  63. 63.
    Katsuki H., Shimada K., Koyama A., Okita M., Yamaguchi Y., Okamoto T.: Long-term intermittent adjuvant chemotherapy for primary, resected lung cancer. J. Thorac. Cardiovasc. Surg. 70, 590 (1975)PubMedGoogle Scholar
  64. 64.
    Kaufmann M., Wirth K., Scheurer J., Zimmermann A., Luscieti P., Stjernswärd J.: Immunomorphological lymph node changes in patients with operable bronchogenic squamous cell carcinoma. Cancer 39, 2371 (1977)PubMedCrossRefGoogle Scholar
  65. 65.
    Kimura I., Ohnoshi T., Yasuhara S., Sugiyama M., Urabe Y., Fujii M., Machida K.: Immunochemotherapy in human lung cancer using the streptococcal agent OK—432. Cancer 37, 2201 (1976)PubMedCrossRefGoogle Scholar
  66. 66.
    Koyama A. : Clinical studies on longterm intermittent adjuvant chemotherapy for lung cancer. J. Jap. Ass. Thorac. Surg. 17, 863 (1969)Google Scholar
  67. 67.
    Kreyberg L. et al.: International histological classification of tumors. 1. Histological typing of lung tumors. WHO, Genf 1967Google Scholar
  68. 68.
    Kutschera W., Schnetzer J.: Zytostatika nach Lungenresektion wegen Krebs. Wr. Klin. Wschr. 77, 289 (1965)Google Scholar
  69. 69.
    Laval P., Besson J., Meyer G., Kleisbauer J.-P., Cesarini J.-P., Rouquette D.: Surveillance des défenses immunitaires au cours du traitement des carcinomas bronchique primitifs. Bulletin du Cancer 58, 91 (1971).PubMedGoogle Scholar
  70. 70.
    Lichtenfeld J. L., Wiernik P. H.: Phase I trial of levamisole (L) in non resectable bronchogenic carcinoma (NRBC). Proc. of the 67th annual meeting of the American Association for Cancer Research, 4.–8. Mai 1976, Toronto; Abstr. 260Google Scholar
  71. 71.
    Likehite V. V.: Experimental cancer immunotherapy: Comparison of tumor rejection in F 344 rats given mycobacterium bovis (strain BCG) and killed C. Parvum. J. Nat. Cancer Inst. 46, 985 (1976)Google Scholar
  72. 72.
    Ludwig Lung Cancer Cooperative Group: Search for the possible role of “immunotherapy” in operable bronchial non-smaIl-cell carcinoma (Stage I and II): A Phase I Study with Corynebacterium parvum intrapieurally. Cancer Immunology and Immunotherapy 4, 69–75 (1978)Google Scholar
  73. 73.
    McKneally M. F., Maver C., Kausel H. W., Alley R. D.: Regional immunotherapy with intrapleural BCG for lung cancer. J. of Thoracic and Cardiovasc. Surg. 72, 333 (1976)Google Scholar
  74. 74.
    McKneally M. F., Maver C. M., Kausel H. W.: Intrapleural BCG immunostimulation in lung cancer. The Lancet I, 595 (1977)Google Scholar
  75. 75.
    Mastrangelo M., Berd D., Belled R. E.: Critical review of previous reported clinical trials of cancer — immunotherapy with non specific immunostimulant. Ann. New York Acad. Scie. 277, 94 (1976)CrossRefGoogle Scholar
  76. 76.
    Mikaelyan S. G., Pirogov A. I., Shiyataya O. K.: Application of the kinetic method for the evaluation of the effectiveness of lung cancer treatment. Izv. Akad. Nauk. SSSR, Ser. Biol. 1, 60 (1973)Google Scholar
  77. 77.
    Morales F., Bell M., McDonald G. O., Cole W. H.: The prophylactic treatment of cancer at the time of operation. Ann. of Surg. 146, 588 (1957)CrossRefGoogle Scholar
  78. 78.
    Mountain C. F.: Keynote address on surgery in the therapy for lung cancer: Surgical prospects and priorities for clinical research. Cancer Chemother. Rep. 4, 19 (1973)Google Scholar
  79. 79.
    Mountain C. F., Carr D. T., Anderson W. A. D.: A system for the clinical staging of lung cancer. Am. J. of Roent., Rad. Ther. and Nucl. Med. 120, 130 (1974)Google Scholar
  80. 80.
    Mountain C. F.: The effectiveness of oral CCNU as an adjuvant to “curative” surgery. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr. 45Google Scholar
  81. 81.
    Newman C. E., Ford C. H. J., Davies D. A. L., O’Neill G. J.: Antibody-drug synergism: an assessment of specific passive immunotherapy in bronchial carcinoma, The Lancet 2, 163 (1977)CrossRefGoogle Scholar
  82. 82.
    Oettgen H. F., Pinsky C. M., Delmonte L.: Treatment of cancer with immunomodulators. Med. Clin. North Amer. 60, 511 (1976)Google Scholar
  83. 83.
    Peterson B. E.: Effectiveness of oral CCNU as an adjuvant to curative surgery. Second National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22—24, 1977Google Scholar
  84. 84.
    Pfeiffer K. M., Middendorp U. G., Marthaler T.: Cytostatische Recidivprophylaxe operierter maligner Tumoren. Schweiz. Med. Wschr. 96, 903 (1966)PubMedGoogle Scholar
  85. 85.
    Pines A.: A 5 years controlled study of BCG and radiotherapy for inoperable lung cancer. The Lancet 1, 380 (1976)CrossRefGoogle Scholar
  86. 86.
    Pirogov A. I., Trakhtenberg A. K.: Late results of the combined (surgical and chemotherapeutic) treatment in pulmonary cancer. Vop. Oncol. 18, 77 (1972)Google Scholar
  87. 87.
    Pirogov A. I., Pavlov A., Trachtenberg A., Volkova M., Maximov U., Matveeva T.: Principal results of combined treatment of lung cancer patients. First National Cancer Institute Conf. on Lung Cancer Treatm., Airlie House, Virginia, Oct. 1972Google Scholar
  88. 88.
    Pirogov A. I., Trakhtenberg A. K.: Results and prospects of combined surgery and antitumor chemotherapy for lung cancer. Cancer Treatm. Rep. 60, 1489 (1976)Google Scholar
  89. 89.
    Pouillart, P., Mathé G., Palangie T., Schwarzenberg L., Huguenin P., Morin P., Gautier M., Parrot R. : Trial of BCG immunotherapy in the treatment of resectable squamous cell carcinoma of the bronchus (stage I and II). Cancer Immunol. Immunother. 1, 271 (1976)Google Scholar
  90. 90.
    Pouillart P., Mathé G., Palangie T., Huguenin P., Morin P., Gautier H., Baron A., Ledente A.: Immunotherapy of resectable squamous cell carcinoma of the bronchus (stage I and II). Second Nat. Cancer Inst. Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24, 1977, Abstr.53Google Scholar
  91. 91.
    Pouillart P., Mathé G., Palangie T., Huguenin P., Morin P., Gautier H., Baron A., Lededente A.: Pre-chemotherapy (CT) adjuvant immunotherapy of stage III and IV bronchus carcinoma (BC). 2nd Nat. Cancer Inst. Conference on Lung Cancer Treatment, Airlie House, Virginia, 22.–24. Mai 1977; Abstr. 54Google Scholar
  92. 92.
    Poulsen O.: Prae- und postoperative cytostatische Behandlung von Lungenkarzinomen mit Cyclophosphamid. Arzneimittel-Forschung 11, 238 (1961)PubMedGoogle Scholar
  93. 93.
    Poulsen O.: Reduction of late metastases and ultimate destruction of malignant tissue by cyclophosphamide as adjuvant in surgery of human lung cancer. IX. Intern. Congr. of Cancer, Tokyo 1966Google Scholar
  94. 94.
    Rall D. P. : New approaches in administration of anticancer drugs. Cancer Res. 29, 2471 (1969)PubMedGoogle Scholar
  95. 95.
    Ritts R. E.: The rationale for immunoprophylaxis in resectable early lung cancer. 2nd Nat. Cancer Inst. Conference on Lung Cancer Treatment, Airlie House, Virginia, 22.–24. Mai 1977; Abstr. 57Google Scholar
  96. 96.
    Robinson E. : The effects of methanol extraction residue of BCG on patients with advanced lung cancer. 12th annual meeting of the American Society of Clinical Oncology, 4.–8. Mai 1976; Toronto, Abstr. C-280Google Scholar
  97. 97.
    Ruckdeschel J. C., Codish St. D., Stranahan A., McKneally M. F.: Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. New Engl. J. of Med. 287, 1013 (1972)CrossRefGoogle Scholar
  98. 98.
    Salzer G.: Vorschlag einer Einteilung des Bronchuskarzinomes nach pathologisch-anatomischklinischen Gesichtspunkten. Wr. Med. Wochenschr. 101, 102 (1,951)Google Scholar
  99. 99.
    Salzer G.: Behandlungsergebnisse im Frühstadium des Lungenkrebses. Wr. Med. Wochenschr. 75, 888 (1963)Google Scholar
  100. 100.
    Salzer G.: Klinische Überlegungen zur Histologie des Bronchuskarzinomes. Das Fiasko der Klassifizierung. Thoraxchirurgie Vask. Chir. 15, 121 (1967)Google Scholar
  101. 101.
    Scadding J. G.: Study of cytotoxic chemotherapy as an adjuvant to surgery in Carcinoma of the bronchus. Brit. Med. J. 2, 421 (1971)CrossRefGoogle Scholar
  102. 102.
    Scott M. T.: Corynebacterium parvum as an immunotherapeutic anticancer agent. Seminars in Oncology 1, 367 (1974)PubMedGoogle Scholar
  103. 103.
    Shields Th. W., Robinette D., Keehn R. J.: Bronchial carcinoma treated by adjuvant cancer chemotherapy. Arch. of Surg. 109, 329 (1974)Google Scholar
  104. 104.
    Skipper H. E.: Combination therapy: Some concepts and results. Cancer Chemother. Rep. 4, 137 (1974)Google Scholar
  105. 105.
    Slack N. H.: Bronchogenic carcinoma: Nitrogen mustard as a surgical adjuvant and factors influencing survival. Cancer 25, 987 (1970)PubMedCrossRefGoogle Scholar
  106. 106.
    Schabel F. M. Jr.: Drug treatment of malignant tumors of man and animals – A rational approach to cancer chemotherapy. Bulletin of the Southern Med. Ass. 57, 40 (1969)Google Scholar
  107. 107.
    Schabel F. M.: Rationale for adjuvant chemotherapy. Cancer 39/6 Suppl., 2875 (1977)Google Scholar
  108. 108.
    Stott H., Stephens R. J., Fox W., Roy D. C.: 5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br. J. of Cancer 34, 167 (1976)CrossRefGoogle Scholar
  109. 109.
    Straus M. J.: Lung Cancer: 1974, Sem. in Oncol. 1, 285 (1974)Google Scholar
  110. 110.
    Street E. W.: Effective chemotherapy for bronchial carcinoma. Paper — 9th Intern. Congress of Chemotherapy, 16. Juli 1975Google Scholar
  111. 111.
    Takita H., Brugarolas A.: Adjuvant immunotherapy for bronchogenic carcinoma: Preliminary results. Cancer Chemother. Rep. 4, 293 (1973)Google Scholar
  112. 112.
    Takita H., Moayeri H.: Effects of corynebacterium parvum and chemotherapy in lung carcinomas. 12th annual meeting of the American Society of Clinical Oncology, Toronto 4.–8. Mai 1976: Abstr. C-221Google Scholar
  113. 113.
    Takita H., Evans J. T., Han T., Minowada J., Cohen E.: Thoracic duct cannulation in a patient with lung cancer. J. of Sur. Oncol. 8, 143 (1976)CrossRefGoogle Scholar
  114. 114.
    Tanneberger S., Jacobasch K., Matthes T., Matthias M., Morack, G., Peek U., Pockrandt H., Rieche K., Widow W.: Actual results of two randomized clinical trials evaluating in vitro predicted postoperative chemotherapy (lung cancer, ovarian cancer). 9th Intern. Congr. of Chemother., London 1975, Abstr. C-89Google Scholar
  115. 115.
    UICO, Union Internationale Contre Ie Cancer: Clinical stage classification and presentation of results. The TNM-system. Description of the extent of the disease — general rules. WId. Hlth. Org. techno Rep. Ser. 53 (1952)Google Scholar
  116. 116.
    UICC, Union Internationale Contre Ie Cancer: TNM classification of malignant tumors. Geneva (1968)Google Scholar
  117. 117.
    Urabe M., Yamamoto K., Kobayashi T., Tsunamura S.: Study on chemotherapy of malignant tumors. Study on Mitomycin 120, 1 (1961)Google Scholar
  118. 118.
    Urist M. M., Boddie A. W., Townsend C. M., Holmes E. C.: In vitro evidence for increased cellular immunity to lung cancer antigen during levamisole immunotherapy. J. Thor. Cardiovase. Surg. 73, 189 (1977)Google Scholar
  119. 119.
    Viadana E., Bross I. D. J., Pickren J. W.: The relationship of histology to the spread of cancer. J. Surg. Oncol. 7, 177 (1975)PubMedCrossRefGoogle Scholar
  120. 120.
    Weiss W.: The mitotic index in bronchogenic carcinoma. Amer. Rev. Resp. Dis. 104, 536 (1971)PubMedGoogle Scholar
  121. 121.
    Weiss W., Gillick J. S.: The metastatic spread of bronchogenic carcinoma in relation to the interval between resection and death. Chest 71, 725 (1977)PubMedCrossRefGoogle Scholar
  122. 122.
    Wilde J.: Probleme der Chemotherapie beim operierten Bronchialkarzinom. Zschr. Erkr. Atm. 142, 101 (1975)Google Scholar
  123. 123.
    Wingfield H. V.: Combined surgery and chemotherapy for carcinoma of the bronchus. The Lancet 1, 470 (1970)CrossRefGoogle Scholar
  124. 124.
    Woodruff M. F. A., Dunbar N.: The effect of corynebacterium parvum and other reticuloendothelial stimulants on transplanted tumors in mice. Immunopotentiation, Ciba Found. Symp. 18, 287 (1973)CrossRefGoogle Scholar
  125. 125.
    Wurnig P.: Zur Methode der Beurteilung kurativer Erfolge der Carcinomchirurgie an Hand des Bronchuscarcinoms. Thoraxchir. 2, 281 (1954)Google Scholar
  126. 126.
    Wurnig P.: Ergebnisse und Grundsätze der Rezidivprophylaxe mit Mitomen bei radikal operierten malignen Tumoren an Hand des Bronchuskarzinoms. Wr. Klin. Wschr. 70, 63 (1958)Google Scholar
  127. 127.
    Wurnig P., Scheuba G., Karrer K.: Vorläufige Ergebnisse der chemotherapeutischen Rezidivprophylaxe mit Mitomen beim operierten Bronchuscarcinom. Acta Vnion Int. Contre le Cancer 16, 935 (1960)Google Scholar
  128. 128.
    Yamamura Y.: Immunotherapy of lung cancer with oil-attached cell-wall skeletons of M. bovis BCG and N.rubra. Second Nat. Cancer Inst. Conf. on Lung Cancer Treatm., Airlie House, Virginia, May 22–24,1977, Abstr. 74Google Scholar
  129. 129.
    Yasumoto K., Manabe H., Ueno M., Ohta M., Ueda H., Iida A., Yamamura Y., Azuma I.: Immunotherapy of human lung cancer with BCG cell wall skeleton. Gann 67, 787 (1976)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1978

Authors and Affiliations

  • K Karrer
    • 1
  1. 1.Institut für KrebsforschungUniversität WienDeutschland

Personalised recommendations